High-Risk Acute Myeloid Leukemia: A Pediatric Prospective

被引:2
作者
Cacace, Fabiana [1 ]
Iula, Rossella [2 ]
De Novellis, Danilo [3 ]
Caprioli, Valeria [1 ]
D'Amico, Maria Rosaria [1 ]
De Simone, Giuseppina [1 ]
Cuccurullo, Rosanna [4 ]
Wierda, William G. [5 ]
Mahadeo, Kris Michael [6 ]
Menna, Giuseppe [4 ]
Tambaro, Francesco Paolo [1 ]
机构
[1] Azienda Osped Rilievo Nazl Santobono Pausilipon, Unita Operat Trapianto Cellule Staminali Ematopoi, I-80123 Naples, Italy
[2] Azienda Osped Univ Federico II, Dipartimento Med Clin & Chirurg, I-80100 Naples, Italy
[3] Osped San Giovanni Dio & Ruggi DAragona, Ctr Ematol & Trapianto, I-84131 Salerno, Italy
[4] Azienda Osped Rilievo Nazl Santobono Pausilipon, Unita Operat Ematol, I-80123 Naples, Italy
[5] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[6] Univ Texas MD Anderson Canc Ctr, CARTOX Program, Pediat Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
关键词
AML; pediatric; risk stratification; outcome; target therapy; CHIMERIC ANTIGEN RECEPTOR; CONVENTIONAL CARE REGIMENS; ACUTE MYELOGENOUS LEUKEMIA; REFRACTORY SOLID TUMORS; STEM-CELL FACTOR; GEMTUZUMAB OZOGAMICIN; MYELODYSPLASTIC SYNDROMES; PROGNOSTIC-SIGNIFICANCE; OLDER PATIENTS; OPEN-LABEL;
D O I
10.3390/biomedicines10061405
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Pediatric acute myeloid leukemia is a clonal disorder characterized by malignant transformation of the hematopoietic stem cell. The incidence and the outcome remain inferior when compared to pediatric ALL, although prognosis has improved in the last decades, with 80% overall survival rate reported in some studies. The standard therapeutic approach is a combined cytarabine and anthracycline-based regimen followed by consolidation with allogeneic stem cell transplantation (allo-SCT) for high-risk AML and allo-SCT for non-high-risk patients only in second complete remission after relapse. In the last decade, several drugs have been used in clinical trials to improve outcomes in pediatric AML treatment.
引用
收藏
页数:18
相关论文
共 140 条
[1]   Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors [J].
Abrams, Tinya ;
Connor, Anu ;
Fanton, Christie ;
Cohen, Steven B. ;
Huber, Thomas ;
Miller, Kathy ;
Hong, E. Erica ;
Niu, Xiaohong ;
Kline, Janine ;
Ison-Dugenny, Marjorie ;
Harris, Sarah ;
Walker, Dana ;
Krauser, Klaus ;
Galimi, Francesco ;
Wang, Zhen ;
Ghoddusi, Majid ;
Mansfield, Keith ;
Lee-Hoeflich, Si Tuen ;
Holash, Jocelyn ;
Pryer, Nancy ;
Kluwe, William ;
Ettenberg, Seth A. ;
Sellers, William R. ;
Lees, Emma ;
Kwon, Paul ;
Abraham, Judith A. ;
Schleyer, Siew C. .
CLINICAL CANCER RESEARCH, 2018, 24 (17) :4297-4308
[2]   PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation [J].
Albring, J. C. ;
Inselmann, S. ;
Sauer, T. ;
Schliemann, C. ;
Altvater, B. ;
Kailayangiri, S. ;
Roessig, C. ;
Hartmann, W. ;
Knorrenschild, J. R. ;
Sohlbach, K. ;
Groth, C. ;
Lohoff, M. ;
Neubauer, A. ;
Berdel, W. E. ;
Burchert, A. ;
Stelljes, M. .
BONE MARROW TRANSPLANTATION, 2017, 52 (02) :317-320
[3]   Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges [J].
Alfayez, Mansour ;
Borthakur, Gautam .
EXPERT REVIEW OF HEMATOLOGY, 2018, 11 (05) :373-389
[4]   The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia [J].
Ali, Sahra ;
Dunmore, Helen-Marie ;
Karres, Dominik ;
Hay, Justin L. ;
Salmonsson, Tomas ;
Gisselbrecht, Christian ;
Sarac, Sinan B. ;
Bjerrum, Ole W. ;
Hovgaard, Doris ;
Barbachano, Yolanda ;
Nagercoil, Nithyanandan ;
Pignatti, Francesco .
ONCOLOGIST, 2019, 24 (05) :E171-E179
[5]   Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial [J].
Amadori, Sergio ;
Suciu, Stefan ;
Selleslag, Dominik ;
Aversa, Franco ;
Gaidano, Gianluca ;
Musso, Maurizio ;
Annino, Luciana ;
Venditti, Adriano ;
Voso, Maria Teresa ;
Mazzone, Carla ;
Magro, Domenico ;
De Fabritiis, Paolo ;
Muus, Petra ;
Alimena, Giuliana ;
Mancini, Marco ;
Hagemeijer, Anne ;
Paoloni, Francesca ;
Vignetti, Marco ;
Fazi, Paola ;
Meert, Liv ;
Ramadan, Safaa Mahmoud ;
Willemze, Roel ;
de Witte, Theo ;
Baron, Frederic .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (09) :972-+
[6]   Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Group [J].
Aplenc, Richard ;
Meshinchi, Soheil ;
Sung, Lillian ;
Alonzo, Todd ;
Choi, John ;
Fisher, Brian ;
Gerbing, Robert ;
Hirsch, Betsy ;
Horton, Terzah ;
Kahwash, Samir ;
Levine, John ;
Loken, Michael ;
Brodersen, Lisa ;
Pollard, Jessica ;
Raimondi, Susana ;
Kolb, Edward Anders ;
Gamis, Alan .
HAEMATOLOGICA, 2020, 105 (07) :1879-1886
[7]   The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know [J].
Arber, Daniel A. .
SEMINARS IN HEMATOLOGY, 2019, 56 (02) :90-95
[8]   The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].
Arber, Daniel A. ;
Orazi, Attilio ;
Hasserjian, Robert ;
Thiele, Jurgen ;
Borowitz, Michael J. ;
Le Beau, Michelle M. ;
Bloomfield, Clara D. ;
Cazzola, Mario ;
Vardiman, James W. .
BLOOD, 2016, 127 (20) :2391-2405
[9]   Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia [J].
Arceci, RJ ;
Sande, J ;
Lange, B ;
Shannon, K ;
Franklin, J ;
Hutchinson, R ;
Vik, TA ;
Flowers, D ;
Aplenc, R ;
Berger, MS ;
Sherman, ML ;
Smith, FO ;
Bernstein, I ;
Sievers, EL .
BLOOD, 2005, 106 (04) :1183-1188
[10]   The biology of stem cell factor and its receptor C-kit [J].
Ashman, LK .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 1999, 31 (10) :1037-1051